Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00080236 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation
A Phase 2 study, sponsored by Conatus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
NCT00080236 is a Phase 2 study that has completed, run by Conatus Pharmaceuticals. The registered enrollment target is 99 participants.
The verdict
NCT00080236, a Phase 2 study, has completed, sponsored by Conatus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
Study Summary
The purpose of the study is to test the safety and effectiveness of IDN-6556 in preventing liver damage that normally occurs when livers are transported before being transplanted and in the immediate post-transplant period.
Interventions
- DRUG Placebo
- DRUG IDN-6556
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2003-11 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00080236
The ClinicalTrials.gov registry entry for NCT00080236 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Conatus Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00080236 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00080236 about?
NCT00080236 is a clinical study titled "Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation". The purpose of the study is to test the safety and effectiveness of IDN-6556 in preventing liver damage that normally occurs when livers are transported before being transplanted and in the immediate post-transplant period.
What is the current status of trial NCT00080236?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2003-11. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00080236?
The interventions under investigation include: Placebo (DRUG), IDN-6556 (DRUG).
Who is sponsoring clinical trial NCT00080236?
This trial is sponsored by Conatus Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.